Novel Personalized Non Invasive Combined Magnetic and Electrical Stimulation of the DMN in Mild AD Patients

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50-85
SponsorI.R.C.C.S. Fondazione Santa Lucia

About this trial

Alzheimer's disease (AD) is increasingly recognized as a disorder marked by early synaptic dysfunction and disrupted brain network connectivity, beyond the traditional focus on amyloid pathology. Synaptic plasticity (crucial for learning and memory) is compromised in AD and represents a promising therapeutic target. In particular, alterations in the Default Mode Network (DMN), especially in regions like the precuneus, suggest that restoring connectivity and enhancing plasticity may improve cognitive outcomes. This project proposes a novel, precision-delivered non-invasive brain stimulation protocol that combines repetitive transcranial magnetic stimulation (rTMS) and transcranial alternating current stimulation (tACS) over the DMN. The intervention will be evaluated through cognitive testing, blood-based biomarkers, MRI and TMS-EEG, alongside immersive virtual environments to assess sensorimotor and cognitive function. This approach aims to test neuromodulation strategies capable of slowing neurodegeneration and supporting early detection and rehabilitation in AD.

Eligibility criteria

Qualifiers

Patients with a diagnosis of AD according to IWG criteria

20 > MMSE < 28

Patients with CSF specific biomarker profile or with a positive Amyloid Pet Scan consistent with the presence of amyloid pathology

Global Clinical Dementia Rating (CDR) ≤1

Disqualifiers

Failure to undergo screening or baseline exams

Hospitalization or change in chronic concomitant medications one month before the screening or during the screening period

other primary degenerative dementia (Lewy body dementia, frontotemporal dementia, Huntington's disease, Creutzfeldt-Jakob disease, Down syndrome, etc.);

other neurodegenerative conditions (Parkinson's disease, amyotrophic lateral sclerosis, etc.);

Trial design

Treatments tested in this trial

  • Combined iTBS-tACS
  • iTBS-sham tACS
  • sham iTBS- sham tACS

Treatment groups

60 Participants
are divided into 3 treatment groups

Sponsors and collaborators

I.R.C.C.S. Fondazione Santa Lucia

Lead sponsor

IRCCS Centro Neurolesi Bonino Pulejo

Collaborator